Yumiko Moritani

893 total citations
16 papers, 725 citations indexed

About

Yumiko Moritani is a scholar working on Hematology, Cardiology and Cardiovascular Medicine and Molecular Biology. According to data from OpenAlex, Yumiko Moritani has authored 16 papers receiving a total of 725 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 8 papers in Cardiology and Cardiovascular Medicine and 4 papers in Molecular Biology. Recurrent topics in Yumiko Moritani's work include Blood Coagulation and Thrombosis Mechanisms (7 papers), Antiplatelet Therapy and Cardiovascular Diseases (6 papers) and Atrial Fibrillation Management and Outcomes (4 papers). Yumiko Moritani is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (7 papers), Antiplatelet Therapy and Cardiovascular Diseases (6 papers) and Atrial Fibrillation Management and Outcomes (4 papers). Yumiko Moritani collaborates with scholars based in Japan and Netherlands. Yumiko Moritani's co-authors include Tomihisa Kawasaki, Kazumi Hayashi, Masatoshi Taniguchi, Tetsu Saito, Jun Takasaki, Masato Kobori, Koji Nagai, Shin‐ichi Tsukamoto, Takeshi Shigenaga and Yoshiyuki Iwatsuki and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Journal of Medicinal Chemistry.

In The Last Decade

Yumiko Moritani

16 papers receiving 707 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yumiko Moritani Japan 12 453 144 129 103 66 16 725
M M L Davidson Canada 9 273 0.6× 46 0.3× 113 0.9× 129 1.3× 43 0.7× 11 576
Kayoko Mihara Japan 12 298 0.7× 67 0.5× 90 0.7× 72 0.7× 7 0.1× 19 672
Marjo Pihlavisto Finland 17 591 1.3× 202 1.4× 14 0.1× 19 0.2× 35 0.5× 28 786
John A. Mitchell United States 10 404 0.9× 50 0.3× 39 0.3× 26 0.3× 24 0.4× 18 777
Debra J. Gawler United Kingdom 17 680 1.5× 124 0.9× 103 0.8× 35 0.3× 34 0.5× 26 868
Lucy H. Elliott United Kingdom 10 490 1.1× 85 0.6× 43 0.3× 44 0.4× 39 0.6× 12 782
Candace Strang United States 13 486 1.1× 85 0.6× 98 0.8× 73 0.7× 15 0.2× 17 724
Victoria P. Knutson United States 17 709 1.6× 79 0.5× 40 0.3× 30 0.3× 38 0.6× 24 1.1k
E. Tsukuda Japan 6 352 0.8× 59 0.4× 56 0.4× 16 0.2× 33 0.5× 10 516
Kozui Shii Japan 23 968 2.1× 157 1.1× 138 1.1× 43 0.4× 31 0.5× 46 1.5k

Countries citing papers authored by Yumiko Moritani

Since Specialization
Citations

This map shows the geographic impact of Yumiko Moritani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yumiko Moritani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yumiko Moritani more than expected).

Fields of papers citing papers by Yumiko Moritani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yumiko Moritani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yumiko Moritani. The network helps show where Yumiko Moritani may publish in the future.

Co-authorship network of co-authors of Yumiko Moritani

This figure shows the co-authorship network connecting the top 25 collaborators of Yumiko Moritani. A scholar is included among the top collaborators of Yumiko Moritani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yumiko Moritani. Yumiko Moritani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Kawasaki, Tomihisa, et al.. (2017). Inhibitory effects of ASP6537, a selective cyclooxygenase-1 inhibitor, on thrombosis and neointima formation in rats. Thrombosis Research. 157. 72–78. 2 indexed citations
2.
Hirayama, Fukushi, Hiroyuki Koshio, Tsukasa Ishihara, et al.. (2011). Discovery of N -[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (Darexaban, YM150) as a Potent and Orally Available Factor Xa Inhibitor. Journal of Medicinal Chemistry. 54(23). 8051–8065. 27 indexed citations
3.
Iwatsuki, Yoshiyuki, Yumiko Moritani, Takeshi Shigenaga, et al.. (2011). Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. European Journal of Pharmacology. 673(1-3). 49–55. 31 indexed citations
4.
Kawasaki, Tomihisa, Masatoshi Taniguchi, Yumiko Moritani, et al.. (2006). Biological properties of a specific Gαq/11 inhibitor, YM‐254890, on platelet functions and thrombus formation under high‐shear stress. British Journal of Pharmacology. 148(1). 61–69. 49 indexed citations
5.
Iwatsuki, Yoshiyuki, Takeshi Shigenaga, Yumiko Moritani, et al.. (2006). Biochemical and Pharmacological Profiles of YM150, an Oral Direct Factor Xa Inhibitor.. Blood. 108(11). 911–911. 24 indexed citations
6.
Taniguchi, Masatoshi, Yumiko Moritani, Takeshi Shigenaga, et al.. (2005). Pharmacological properties of YM-254890, a specific Gαq/11 inhibitor, on thrombosis and neointima formation in mice. Thrombosis and Haemostasis. 94(7). 184–192. 37 indexed citations
7.
Koshio, Hiroyuki, Fukushi Hirayama, Tsukasa Ishihara, et al.. (2004). Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives. Bioorganic & Medicinal Chemistry. 12(20). 5415–5426. 12 indexed citations
8.
Iwatsuki, Yoshiyuki, Kazumi Hayashi, Yumiko Moritani, et al.. (2004). Combined effects of a factor Xa inhibitor YM466 and a GPIIb/IIIa antagonist YM128 on thrombosis and neointima formation in mice. Thrombosis and Haemostasis. 92(12). 1221–1228. 12 indexed citations
9.
Takasaki, Jun, Tetsu Saito, Masatoshi Taniguchi, et al.. (2004). A Novel Gαq/11-selective Inhibitor. Journal of Biological Chemistry. 279(46). 47438–47445. 329 indexed citations
10.
Taniguchi, Masatoshi, Ken‐ichi Suzumura, Koji Nagai, et al.. (2004). YM-254890 analogues, novel cyclic depsipeptides with Gαq/11 inhibitory activity from Chromobacterium sp. QS3666. Bioorganic & Medicinal Chemistry. 12(12). 3125–3133. 47 indexed citations
11.
Koshio, Hiroyuki, Fukushi Hirayama, Tsukasa Ishihara, et al.. (2004). Synthesis and biological activity of novel 1,2-disubstituted benzene derivatives as factor Xa inhibitors. Bioorganic & Medicinal Chemistry. 13(4). 1305–1323. 21 indexed citations
12.
Taniguchi, Masatoshi, Yumiko Moritani, Kazumi Hayashi, et al.. (2003). Antithrombotic and thrombolytic efficacy of YM-254890, a Gq/11 inhibitor, in a rat model of arterial thrombosis. Thrombosis and Haemostasis. 90(9). 406–413. 34 indexed citations
13.
Taniguchi, Masatoshi, Koji Nagai, Tomihisa Kawasaki, et al.. (2003). YM-254890, a Novel Platelet Aggregation Inhibitor Produced by Chromobacterium sp. QS3666. The Journal of Antibiotics. 56(4). 358–363. 89 indexed citations
14.
Iwatsuki, Yoshiyuki, Seiji Kaku, Yumiko Moritani, et al.. (2003). Antithrombotic effects of YM466, a synthesized direct inhibitor of factor Xa, in an arterio‐venous shunt thrombosis model in squirrel monkeys. Drug Development Research. 58(2). 190–195. 4 indexed citations
15.
Moritani, Yumiko, Kazuo Sato, Takeshi Shigenaga, et al.. (2002). Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist. European Journal of Pharmacology. 439(1-3). 43–52. 4 indexed citations
16.
Suzuki, Kenichi, Yumiko Moritani, Hiroshi Arai, et al.. (2002). Pharmacodynamics and pharmacokinetics of YM128, a GPIIb/IIIa antagonist prodrug. Drug Development Research. 55(3). 149–161. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M M L Davidson Breakdown of academic impact, for papers by Kayoko Mihara Breakdown of academic impact, for papers by Marjo Pihlavisto Breakdown of academic impact, for papers by John A. Mitchell Breakdown of academic impact, for papers by Debra J. Gawler Breakdown of academic impact, for papers by Lucy H. Elliott Breakdown of academic impact, for papers by Candace Strang Breakdown of academic impact, for papers by Victoria P. Knutson Breakdown of academic impact, for papers by E. Tsukuda Breakdown of academic impact, for papers by Kozui Shii
Rankless by CCL
2026